EPS for Progenics Pharmaceuticals, Inc. (PGNX) Expected At $-0.20; Morgan Stanley Increased Its Dte Energy Co (DTE) Holding

July 17, 2017 - By test

Analysts expect Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report $-0.20 EPS on August, 3.They anticipate $0.12 EPS change or 150.00% from last quarter’s $-0.08 EPS. After having $-0.23 EPS previously, Progenics Pharmaceuticals, Inc.’s analysts see -13.04% EPS growth. About 538,956 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since July 17, 2016 and is uptrending. It has outperformed by 31.71% the S&P500.

Morgan Stanley increased Dte Energy Co (DTE) stake by 131.64% reported in 2016Q4 SEC filing. Morgan Stanley acquired 562,571 shares as Dte Energy Co (DTE)’s stock rose 8.06%. The Morgan Stanley holds 989,927 shares with $97.52M value, up from 427,356 last quarter. Dte Energy Co now has $19.10B valuation. The stock rose 0.54% or $0.57 reaching $105.96 per share. About 572,796 shares traded. DTE Energy Co (NYSE:DTE) has risen 19.61% since July 17, 2016 and is uptrending. It has outperformed by 2.91% the S&P500.

Since February 7, 2017, it had 0 buys, and 2 insider sales for $9.23 million activity. 351,300 Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares with value of $3.41M were sold by Broadfin Healthcare Master Fund Ltd.

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The company has market cap of $478.94 million. The Company’s pipeline includes therapeutic agents designed to target cancer ; prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It has a 66.52 P/E ratio. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 9 analyst reports since August 6, 2015 according to SRatingsIntel. Needham maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Tuesday, June 20 with “Buy” rating. The firm has “Buy” rating by Needham given on Friday, August 7. The rating was maintained by Brean Capital with “Buy” on Thursday, August 6. As per Friday, October 23, the company rating was upgraded by Jefferies. The firm earned “Buy” rating on Thursday, June 8 by Jefferies. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Strong Buy” rating by Needham on Monday, February 6. The stock has “Buy” rating by Aegis Capital on Thursday, October 27. The stock has “Buy” rating by Zacks on Friday, August 7.

Investors sentiment increased to 1.22 in Q4 2016. Its up 0.05, from 1.17 in 2016Q3. It increased, as 12 investors sold Progenics Pharmaceuticals, Inc. shares while 38 reduced holdings. 31 funds opened positions while 30 raised stakes. 59.59 million shares or 0.65% more from 59.20 million shares in 2016Q3 were reported. Tower Rech Lc (Trc) owns 3,412 shares. Dekabank Deutsche Girozentrale, Germany-based fund reported 10,000 shares. Alliancebernstein Limited Partnership, New York-based fund reported 453,842 shares. Moreover, Tiaa Cref Invest Ltd Liability Corporation has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Susquehanna Gru Limited Liability Partnership stated it has 197,616 shares or 0% of all its holdings. Schwab Charles Invest Mgmt holds 0% or 274,933 shares. Legal And General Group Incorporated Pcl reported 0% stake. Parametric Assoc Lc holds 0% or 75,836 shares in its portfolio. Great West Life Assurance Can has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Clear Harbor Asset Mgmt Lc stated it has 0.1% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). State Bank Of Ny Mellon stated it has 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Gsa Partners Limited Liability Partnership holds 0.01% or 18,890 shares in its portfolio. Proshare Ltd Liability reported 57,459 shares stake. Gotham Asset Ltd Company holds 529,614 shares. Mark Sheptoff Fincl Planning Ltd Company invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Investors sentiment decreased to 1.04 in Q4 2016. Its down 0.44, from 1.48 in 2016Q3. It dived, as 49 investors sold DTE shares while 167 reduced holdings. 60 funds opened positions while 164 raised stakes. 119.36 million shares or 1.43% more from 117.67 million shares in 2016Q3 were reported. Cantab Prtn Ltd Liability Partnership owns 3,083 shares or 0% of their US portfolio. Bb&T Corp has invested 0.01% in DTE Energy Co (NYSE:DTE). Tci Wealth Advisors stated it has 1,486 shares. Kistler has 0.01% invested in DTE Energy Co (NYSE:DTE) for 131 shares. Blackrock Limited has 1.75M shares. White Pine Investment Company accumulated 8,040 shares. Cwm Ltd owns 2,892 shares for 0.02% of their portfolio. Dubuque State Bank And owns 130 shares. Cetera Advisor Net Llc holds 0.03% or 6,359 shares. Morgan Stanley, a New York-based fund reported 989,927 shares. Cubist Systematic Strategies Lc invested 0.07% of its portfolio in DTE Energy Co (NYSE:DTE). Arvest Fincl Bank Trust Division holds 122,679 shares. The New York-based Art Advisors Limited Liability has invested 0.04% in DTE Energy Co (NYSE:DTE). The Kentucky-based Mcf Limited Com has invested 0.04% in DTE Energy Co (NYSE:DTE). Ny State Common Retirement Fund holds 0.06% or 442,920 shares in its portfolio.

Among 6 analysts covering Dte Energy Company (NYSE:DTE), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Dte Energy Company had 14 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, January 9 by UBS. The stock of DTE Energy Co (NYSE:DTE) has “Buy” rating given on Monday, November 14 by Jefferies. The firm has “Buy” rating given on Thursday, September 29 by UBS. The stock of DTE Energy Co (NYSE:DTE) has “Overweight” rating given on Thursday, April 7 by Barclays Capital. The rating was upgraded by Barclays Capital on Wednesday, January 13 to “Overweight”. The stock of DTE Energy Co (NYSE:DTE) earned “Neutral” rating by Credit Suisse on Wednesday, January 25. Jefferies maintained the stock with “Buy” rating in Friday, April 28 report. The rating was upgraded by Bank of America to “Buy” on Tuesday, November 22.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: